1. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)
- Author
-
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, György Losonczy, Nikolay V Conev, Jon Armstrong, Natalie Byrne, Norah Shire, Haiyi Jiang, Jonathan W Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, Susana Noemi Sena, Juan Jose Zarba, Otto Burghuber, Sylvia Hartl, Bernd Lamprecht, Michael Studnicka, Luis Alberto Schlittler, Fabricio Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Colagiovanni Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Serodio da Rocha Baldotto, Claudia Sette, Mauro Zukin, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Wei Li, Zongan Liang, Zhong Lin, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Vitezslav Kolek, Leona Koubkova, Jaromir Roubec, Jana Skrickova, Milada Zemanova, Christos Chouaid, Werner Hilgers, Hervé Lena, Denis Moro-Sibilot, Gilles Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohe, Eckart Laack, Susanne Lang, Jens Panse, Christian Schulz, Krisztina Bogos, Eszter Csánky, Anea Fülöp, Zsolt Horváth, Judit Kósa, Ibolya Laczó, Gábor Pajkos, Zsuzsanna Pápai, Zsolt Pápai Székely, Veronika Sárosi, Attila Somfay, Éva Somogyiné Ezer, Anás Telekes, Jair Bar, Maya Gottfried, Norman Isaac Heching, Alona Zer Kuch, Roberta Bartolucci, Anna Cecilia Bettini, Angelo Delmonte, Marina Chiara Garassino, Mauro Minelli, Fausto Roila, Shinji Atagi, Koichi Azuma, Hisatsugu Goto, Koichi Goto, Yu Hara, Hidetoshi Hayashi, Toyoaki Hida, Kenya Kanazawa, Shintaro Kanda, Young Hak Kim, Shoichi Kuyama, Tadashi Maeda, Masahiro Morise, Yasuharu Nakahara, Makoto Nishio, Naoyuki Nogami, Isamu Okamoto, Haruhiro Saito, Masahiro Shinoda, Shigeki Umemura, Tatsuya Yoshida, Niels Claessens, Robin Cornelissen, Lizza Heniks, Jeroen Hiltermann, Egbert Smit, Agnes Staal van den Brekel, Dariusz Kowalski, Slawomir Mańdziuk, Robert Mróz, Marek Wojtukiewicz, Tudor Ciuleanu, Doina Ganea, Anei Ungureanu, Alexander Luft, Vladimir Moiseenko, Dina Sakaeva, Alexey Smolin, Alexander Vasilyev, Lyubov Vladimirova, Igor Anasina, Jozef Chovanec, Pavol Demo, Robert Godal, Peter Kasan, Marian Stresko, Michal Urda, Eun Kyung Cho, Joo-Hang Kim, Sang-We Kim, Gyeong-Won Lee, Jong-Seok Lee, Ki Hyeong Lee, Kyung Hee Lee, Yun Gyoo Lee, Maria Amelia Insa Molla, Manuel Domine Gomez, Juan Ignacio Delgado Mingorance, Dolores Isla Casado, Marta Lopez Brea, Margarita Majem Tarruella, Teresa Morán Bueno, Alejano Navarro Mendivil, Luis Paz-Ares Rodríguez, Santiago Ponce Aix, Maria Rosario Garcia Campelo, Gee-Chen Chang, Yen-Hsun Chen, Chao-Hua Chiu, Te-Chun Hsia, Kang-Yun Lee, Chien-Te Li, Chin-Chou Wang, Yu-Feng Wei, Shang-Yin Wu, Ahmet Alacacıoğlu, Irfan Çiçin, Ahmet Demirkazik, Mustafa Erman, Tuncay Göksel, Hryhoriy Adamchuk, Oleksii Kolesnik, Anna Kryzhanivska, Yuriv Ostapenko, Serhii Shevnia, Yaroslav Shparyk, Grygorii Ursol, Nataliia Voitko, Ihor Vynnychenko, Sunil Babu, Anne Chiang, Winston Chua, Shaker Dakhil, Afshin Dowlati, Basir Haque, Rodney Jamil, Jeanna Knoble, Shailena Lakhanpal, Kailhong Mi, Petros Nikolinakos, Steven Powell, Helen Ross, Eric Schaefer, Jeffrey Schneider, Joseph Spahr, David Spigel, Joseph Stilwill, Christopher Sumey, and Michael Williamson
- Subjects
Male ,medicine.medical_specialty ,Lung Neoplasms ,Durvalumab ,Population ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Drug Administration Schedule ,Carboplatin ,03 medical and health sciences ,chemistry.chemical_compound ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,030212 general & internal medicine ,Progression-free survival ,education ,Etoposide ,Aged ,education.field_of_study ,Performance status ,business.industry ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,Interim analysis ,Antineoplastic Agents, Phytogenic ,Small Cell Lung Carcinoma ,Progression-Free Survival ,chemistry ,Female ,Cisplatin ,Prophylactic cranial irradiation ,business ,medicine.drug - Abstract
Background: Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) in treatment-naive patients with ES-SCLC. Methods: This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum–etoposide; durvalumab plus tremelimumab plus platinum–etoposide; or platinum–etoposide alone. All drugs were administered intravenously. Platinum–etoposide consisted of etoposide 80–100 mg/m2 on days 1–3 of each cycle with investigator's choice of either carboplatin area under the curve 5–6 mg/mL per min or cisplatin 75–80 mg/m2 (administered on day 1 of each cycle). Patients received up to four cycles of platinum–etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum–etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the platinum–etoposide group. The primary endpoint was overall survival in the intention-to-treat population. We report results for the durvalumab plus platinum–etoposide group versus the platinum–etoposide group from a planned interim analysis. Safety was assessed in all patients who received at least one dose of their assigned study treatment. This study is registered at ClinicalTrials.gov, NCT03043872, and is ongoing. Findings: Patients were enrolled between March 27, 2017, and May 29, 2018. 268 patients were allocated to the durvalumab plus platinum–etoposide group and 269 to the platinum–etoposide group. Durvalumab plus platinum–etoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0·73 (95% CI 0·59–0·91; p=0·0047]); median overall survival was 13·0 months (95% CI 11·5–14·8) in the durvalumab plus platinum–etoposide group versus 10·3 months (9·3–11·2) in the platinum–etoposide group, with 34% (26·9–41·0) versus 25% (18·4–31·6) of patients alive at 18 months. Any-cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 treated patients in the durvalumab plus platinum–etoposide group and 166 (62%) of 266 in the platinum–etoposide group; adverse events leading to death occurred in 13 (5%) and 15 (6%) patients. Interpretation: First-line durvalumab plus platinum–etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group. Safety findings were consistent with the known safety profiles of all drugs received. Funding: AstraZeneca.
- Published
- 2019